News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AMETEK (AME) Acquires Imago Scientific Instruments


4/8/2010 6:31:32 AM

PAOLI, Pa., April 8 /PRNewswire-FirstCall/ -- AMETEK, Inc. (NYSE:AME - News) today announced that it has acquired Imago Scientific Instruments, a privately held manufacturer of 3D atom probes, based in Madison, WI.

"Imago Scientific Instruments significantly broadens our technical capabilities in differentiated, high-end analytical instrumentation and is an excellent addition to our CAMECA advanced elemental analysis business," states Frank S. Hermance, AMETEK Chairman and Chief Executive Officer.

"Imago is a pioneer in the development of 3D atom probe technology, which is used in advanced materials science to conduct atomic level imaging and analysis. Imago provides us with additional technical capabilities, significantly broadens our customer base and strengthens our global leadership in this high-end technology," notes Mr. Hermance.

"Imago's customers include many of the world's leading academic, government, and industrial research facilities engaged in nanotechnology and other materials science research," he adds.

Imago joins CAMECA as part of AMETEK's Materials Analysis Division, which provides a wide range of complementary imaging and analysis technologies, including secondary ion mass spectrometry (SIMS), low-energy X-ray emission spectrometry (LEXES), electron probe microanalysis (EPMA) instruments, and optical emission and X-ray fluorescence spectrometers for the metals, environmental, R&D, petrochemical, pharmaceutical, electronics and forensic science markets.

Corporate Profile

AMETEK is a leading global manufacturer of electronic instruments and electromechanical devices with annual sales of $2.1 billion. AMETEK's Corporate Growth Plan is based on Four Key Strategies: Operational Excellence, Strategic Acquisitions & Alliances, Global & Market Expansion and New Products. AMETEK's objective is double-digit percentage growth in earnings per share over the business cycle and a superior return on total capital. The common stock of AMETEK is a component of the S&P MidCap 400 Index and the Russell 1000 Index.

Forward-looking Information

Statements in this news release relating to future events such as AMETEK's expected business and financial performance are "forward-looking statements." Forward-looking statements are subject to various factors and uncertainties that may cause actual results to differ significantly from expectations. These factors and uncertainties include our ability to consummate and successfully integrate future acquisitions; risks associated with international sales and operations; our ability to successfully develop new products, open new facilities or transfer product lines; the price and availability of raw materials; compliance with government regulations, including environmental regulations; changes in the competitive environment or the effects of competition in our markets; the ability to maintain adequate liquidity and financing sources; and general economic conditions affecting the industries we serve. A detailed discussion of these and other factors that may affect our future results is contained in AMETEK's filings with the Securities and Exchange Commission, including its most recent reports on Form 10-K, 10-Q and 8-K. AMETEK disclaims any intention or obligation to update or revise any forward-looking statements.

Contact: William J. Burke (610) 889-5249


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES